Evaxion Biotech A/S reported a capital increase to DKK 78,957,151.50 following a public offering of 3,997,361 American Depositary Shares (ADSs) at $2.71 each, effective January 31, 2025. The issuance included providing up to 1,998,675 warrants to purchase ADSs, further amendments to their Articles of Association were made on January 31, February 5, and February 6, 2025.